New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain
This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Glycopyrrolate Oral Solution is an anticholinergic medication indicated for pediatric patients
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Subscribe To Our Newsletter & Stay Updated
